Overview

An Extension Study to Evaluate the Long-Term Safety and Tolerability of Ubrogepant in the Treatment of Migraine

Status:
Completed
Trial end date:
2018-08-02
Target enrollment:
0
Participant gender:
All
Summary
This study will evaluate the long-term safety and tolerability of intermittent treatment with ubrogepant for the acute treatment of migraine over 1 year.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Allergan
Criteria
Inclusion Criteria:

-Completed study UBR-MD-01(NCT02828020) or UBR-MD-02(NCT02867709).

Exclusion Criteria:

- Patients with clinically significant electrocardiogram (ECG), vital sign, physical
exam, or laboratory abnormalities

- Requirement for a medication during the study that is on the list of prohibited
medications.